{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:44:03Z","timestamp":1779147843894,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"ALZA Corporation"},{"DOI":"10.13039\/100014489","name":"Johnson & Johnson Pharmaceutical Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Discuss the current prevalence of Kaposi's sarcoma complicating HIV infection.Describe the impact of highly active antiretroviral therapy (HAART) on Kaposi's sarcoma complicating HIV infection.Prioritize treatment options for Kaposi's sarcoma complicating HIV infection.<\/jats:p>\n                  <jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.12-1-114","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T00:25:32Z","timestamp":1168993532000},"page":"114-123","source":"Crossref","is-referenced-by-count":68,"title":["A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma"],"prefix":"10.1093","volume":"12","author":[{"given":"Timothy","family":"Cooley","sequence":"first","affiliation":[{"name":"a Lahey Clinic, Burlington, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[{"name":"b Pennsylvania Hospital, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Tonda","sequence":"additional","affiliation":[{"name":"c ALZA Corporation, Mountain View, California,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Sun","sequence":"additional","affiliation":[{"name":"d Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"O'Connell","sequence":"additional","affiliation":[{"name":"c ALZA Corporation, Mountain View, California,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Rackoff","sequence":"additional","affiliation":[{"name":"d Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,1,1]]},"reference":[{"key":"2021122208300395700_R1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bmj.319.7201.23","article-title":"Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. Swiss HIV Cohort Study","volume":"319","author":"Ledergerber","year":"1999","journal-title":"BMJ"},{"issue":"suppl 1","key":"2021122208300395700_R2","first-page":"S34","article-title":"Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study","volume":"21","author":"Jacobson","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021122208300395700_R3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ijc.10274","article-title":"Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma","volume":"98","author":"Tam","year":"2002","journal-title":"Int J Cancer"},{"key":"2021122208300395700_R4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00126334-200007010-00013","article-title":"Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy","volume":"24","author":"Jones","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 1","key":"2021122208300395700_R5","first-page":"S23","article-title":"Combination antiretroviral therapy and incidence of AIDS-related malignancies","volume":"21","author":"Buchbinder","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 1","key":"2021122208300395700_R6","first-page":"S31","article-title":"Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants","volume":"21","author":"Rabkin","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021122208300395700_R7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/jnci\/92.22.1823","article-title":"Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults","volume":"92","author":"International Collaboration on HIV and Cancer","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"2021122208300395700_R8","first-page":"S18","article-title":"Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center","volume":"21","author":"Sparano","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021122208300395700_R9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ijc.10790","article-title":"Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy","volume":"103","author":"Carrieri","year":"2003","journal-title":"Int J Cancer"},{"key":"2021122208300395700_R10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2004.08.064","article-title":"Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: Implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma","volume":"22","author":"Krown","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208300395700_R11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/jinf.2001.0810","article-title":"The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic","volume":"42","author":"Ives","year":"2001","journal-title":"J Infect"},{"key":"2021122208300395700_R12","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/01.aids.0000131385.60974.b9","article-title":"Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active anti-retroviral therapy alone in HIV patients with Kaposi's sarcoma","volume":"18","author":"Martin-Carbonero","year":"2004","journal-title":"AIDS"},{"key":"2021122208300395700_R13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/13543784.13.5.501","article-title":"Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma","volume":"13","author":"Cattelan","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122208300395700_R14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest"},{"key":"2021122208300395700_R15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122208300395700_R16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122208300395700_R17","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0959-8049(01)00053-3","article-title":"Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin","volume":"37","author":"Hengge","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122208300395700_R18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1310\/700B-9QT3-HGN9-Q3FQ","article-title":"Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy","volume":"2","author":"Nunez","year":"2001","journal-title":"HIV Clin Trials"},{"key":"2021122208300395700_R19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1445-5994.1998.tb01553.x","article-title":"A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma","volume":"28","author":"Newell","year":"1998","journal-title":"Aust N Z J Med"},{"key":"2021122208300395700_R20","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122208300395700_R21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"2021122208300395700_R22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1081\/CNV-100104284","article-title":"Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine","volume":"19","author":"Osoba","year":"2001","journal-title":"Cancer Invest"},{"key":"2021122208300395700_R23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00002018-199920050-00002","article-title":"A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma","volume":"20","author":"Nasti","year":"1999","journal-title":"Drug Saf"},{"key":"2021122208300395700_R24","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1997.15.9.3085","article-title":"AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee","volume":"15","author":"Krown","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122208300395700_R25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122208300395700_R26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(04)01570-0","article-title":"Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin","volume":"5","author":"Jones","year":"2004","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-1-114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-1-114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/1\/114\/41834918\/oncolo_12_1_114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/1\/114\/41834918\/oncolo_12_1_114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T14:17:54Z","timestamp":1640182674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/1\/114\/6410020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,1]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-1-114","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,1,1]]},"published":{"date-parts":[[2007,1,1]]}}}